Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
12. Jacobsen S, Petersen J, Ullman S, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand JRheumatol 1999; 28: 75—80.
13. Gripenberg M, Helve T. Outcome of systemic lupus erythematosus: a study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations. Scand J Rheumatol 1991; 20:104—109.
14. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. Medicine 1999; 78: 167—175.
15. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995; 38: 274—283.
16. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus: long-term follow-up of an inception cohort. Arthritis Rheum 1995; 38: 1492—1499.
17. Pistiner M, Wallace DJ, Nessim S, et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55—64.
18. Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984: A nationwide epidemiological study in an unselected population. J Rheumatol 1990; 17: 1162—1167.
19. Stahl-Hallengren C, Jonsen A, Nived O, et al. Incidence studies of systemic lupus erythe-matosus in southern Sweden. increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685— 691.
20. Насонов ЕЛ, Карпов ЮА, Алекберова ЗС и соавт. Антифосфолипидный синдром: кардиологические аспекты. Терапевт. архив 1993; 11: 80—86.
21. Насонов ЕЛ. Атеротромбоз при ревматических заболеваниях: анализ патогенеза. Терапевт. архив, 1998; 9: 92—95.
22. Насонов ЕЛ. Проблема атеротромбоза в ревматологии. Вестник РАМН, 2003; 7: 6— 10.
23. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the
John Hopkins Lupus Cohort: prevalence, recognition by patients, and preventing practices. Medicine 1992; 71: 291—302.
24. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology 2000; 39: 238—244.
25. Aronov C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythe-matosus. Lupus 2000; 9:166—169.
26. Manzi S, Meilahn EN, Rairie JE et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythe-matosus: comparison with the Framingem study. Am J Epidemiol 1997; 145:408—415.
27. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology 2000; 39: 353—359.
28. Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patientas management. Curr Opin Rheumatol 2001; 13: 341—344.
29. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus ery-thematosus. Rheum Dis Clin North Amer 2000; 26: 257—278.
30. Manzi S, Wasco MCM. Inflammation-mediated rheumatic disease and atherosclerosis. Ann Rheum Dis 2000; 59: 321—325.
31. Urowitz M, Gladman D, Bruce I. Atherosclerosis and Systemic Lupus Erythematosus. Curr Opin Rheumatoе 2000; 2: 19—23.
32. Jimenez S, Ramos-Cassals M, Cervera R, et al. Atherosclerosis in systemic lupus erythe-matosus: clinical relevance In. Atherosclerosis and autoimmunity Ed. Y Schoenfeld, D. Harats, G Wick. Elsevier 2001:255—265.
33. Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the cause and possible prevention. HKMJ 2002; 8: 26—32.
34. Urowitz MB, Bookman AAM, Koehler BE: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60: 221—225.
35. Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349: 2399—2406.
36. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in sys-
SHS-OOO4.qxd 21.11.2006 16:56 Page 3 3-0
Насонов Е.Л. Антифосфолипидный синдром.
temic lupus erythematosus. New Engl J Med 2003; 349:2407—2415.
37. Badui E, Garcia-Rubi D, Robles E, et al. Cardiovascular manifestations in systemic lupus erythematosus: prospective study in 100 patients. Angiology 1985; 36: 431—441.
38. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14; S13: 223—226
39. Jonsson H, Nived O, Sturfeit G. Outcome in systemic lupus erythematosus: a prospective study of patients from defined population. Medicine (Baltimore) 1989; 42: 338—346.
40. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factor for coronary arthery disease in patients with systemic lupus erythe-matosus. Am J Med 1992; 93: 513—519.
41. Heart-Holmes M, Baethege BA, Brooadwell L, Wolf RE. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995; 22: 450—454.
42. Ward MM. Premature morbidity from cardiovascular disease in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338— 346.
